GN-HEARING
2.4.2020 10:41:08 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid technology, today announced the introduction of ReSound Assist Live, a real-time video-enabled hearing care service. At a time when elderly, more vulnerable populations are advised to stay home, this innovative telehealth solution enables people, from the comfort and safety of their home, to connect with their hearing care professional for new hearing aids and care remotely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005306/en/
GN Hearing recognizes that COVID-19 may seriously affect people who use hearing aids due to stricter social distancing measures, ultimately affecting many people’s wellbeing and mental health. Telehealth services can make an important difference in helping people stay connected with loved ones and informed on rapidly changing events while staying at home. People do not have to sacrifice their hearing and can get the help they need to hear better.
With the launch of ReSound Assist Live, people can now have new hearing aids adjusted remotely by their hearing care professional via new at-home video consultations without physically going to a clinic. Additionally, in these difficult times, hearing care professionals can provide new hearing aids for those who have recently completed a hearing test. In collaboration with HearX, a digital health care company focused on mobile hearing screening, testing and video otoscopy, hearing care professionals in the US can also offer drive-through or at-home hearing tests and receive adjustments and counseling via ReSound Assist Live.
“At this critical time, GN Hearing is as committed as always to helping the hearing community where it’s most needed. For many people, staying in touch with loved ones on the phone and online demands great hearing abilities, so getting access to hearing care support is crucial, particularly for those in self-isolation when communicating is imperative for an individual’s wellbeing,” says Gitte Aabo, CEO and President of GN Hearing.
ReSound Assist Live is an update to ReSound Assist, which already lets people request and receive adjustments to their hearing aids remotely, but the new telehealth tech goes further, enabling live video consultations with hearing care professionals for support wherever they are. This allows in-person support over live video and remote fitting of hearing aids all via the ReSound Smart 3D™ app.
“We expect that the introduction of ReSound Assist Live will help more hearing aid users and their hearing care professionals connect via our innovative remote solutions that work for them, regardless of what’s going on in their lives, how much mobility they have during this difficult time, and in the future,” Gitte Aabo continues.
ReSound Assist Live is available on April 2, 2020 in the US, Canada, the U.K., Germany, Australia, New Zealand and Singapore, and globally from May 1. At-home and drive-through hearing tests will be offered shortly in the US.
- ENDS -
NOTES TO EDITORS
ReSound Assist Live enables individualized care from anywhere
New ReSound Assist Live is an extension of the existing ReSound Assist remote fine-tuning services and can be accessed via video call on the ReSound Smart 3D app. It is the only fitting software which offers comprehensive live video and remote adjustment options.
ReSound Assist already lets people request and receive adjustments to their hearing aids remotely, but ReSound Assist Live goes further, enabling them to speak directly to their hearing care professional over a live link. This means they can benefit from instant access to the highest level of care at a convenient time and place.
About ReSound
ReSound hearing aids, available from leading hearing care professionals, have set worldwide standards for quality and intuitive technology. ReSound was the first hearing aid brand to be Made for iPhone and pioneered the development of 2.4 GHz wireless technology. The introduction of the sixth generation of this technology with ReSound LiNX QuattroTM demonstrates that ReSound is the absolute leader in the industry. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn , Facebook and Twitter .
© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005306/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom